LAG-3 Antibody [Unconjugated]

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

LAG-3 (Lymphocyte activation gene-3), also known as CD223, is a member of the immunoglobulin superfamily (IgSF). The mature LAG-3 protein is a 496 amino acid (aa) membrane protein with a 421 aa extracellular region which contains four IgSF domains, a 21 aa transmembrane region and a 54 aa cytoplasmic region. LAG-3 and CD4 molecules share < 20% aa sequence homology but have a similar structure (1, 2). Both molecules bind to MHC class II. LAG-3 binds to MHC class II with higher affinity compared to CD4. Both LAG-3 and CD4 genes are located on the distal part of the short arm of chromosome 12. LAG-3 is an activation-induced molecule, expressed on activated T cells and NK cells, but not on resting T cells. Studies using LAG-3 ^-/- mice have shown significant delay of T cell apoptosis following antigen stimulation and increased size of memory T cells pool following infection (3, 4). It also has been reported that anti-LAG-3 antibodies up-regulate T cell activation by blocking interaction of LAG-3 and MHC class II. The study has demonstrated that LAG-3 is selectively expressed on activated CD4⁺CD25⁺ T_Reg cells and plays a role in their suppressive activity (5). This evidence indicated, unlike the interaction of CD4 with MHC class II that plays a positive role in T cell activation, LAG-3 binds to MHC class II and negatively regulates T cell activation through LAG-3 signaling. On the other hand, studies have shown that binding of LAG-3 to MHC class II molecules on antigen presenting cells induce maturation of dendritic cells and cytokine secretion by monocytes through MHC class II signal transduction (6). Taken together, LAG-3 may have two major functions, it negatively regulates T cells activation through LAG-3 signaling and stimulates antigen presenting cells which express MHC class II.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

We have publications tested in 1 confirmed species: Human.

We have publications tested in 4 applications: Flow Cytometry, Functional Assay, ICC, Western Blot.

Showing Publications 1 - 5 of 5.

Publications using AF2319	Applications	Species
W Scheper, S Kelderman, LF Fanchi, C Linnemann, G Bendle, MAJ de Rooij, C Hirt, R Mezzadra, M Slagter, K Dijkstra, RJC Kluin, P Snaebjorns, K Milne, BH Nelson, H Zijlmans, G Kenter, EE Voest, JBAG Haanen, TN Schumacher Low and variable tumor reactivity of the intratumoral TCR repertoire in human cancers Nat. Med., 2018-12-03;0(0):. 2018-12-03 [PMID: 30510250] (Flow Cytometry, Human)	Flow Cytometry	Human
X Lu, JW Horner, E Paul, X Shang, P Troncoso, P Deng, S Jiang, Q Chang, DJ Spring, P Sharma, JA Zebala, DY Maeda, YA Wang, RA DePinho Effective combinatorial immunotherapy for castration-resistant prostate cancer Nature, 2017-03-20;543(7647):728-732. 2017-03-20 [PMID: 28321130] (Functional Assay, Human)	Functional Assay	Human
Fine needle aspirate flow cytometric phenotyping characterizes immunosuppressive nature of the mesothelioma microenvironment Sci Rep, 2016-08-19;6(0):31745. 2016-08-19 [PMID: 27539742] (Flow Cytometry, Human)	Flow Cytometry	Human
Bae J, Lee S, Park C, Lee Y, Chun T Trafficking of LAG-3 to the surface on activated T cells via its cytoplasmic domain and protein kinase C signaling. J Immunol, 2014-08-08;193(6):3101-12. 2014-08-08 [PMID: 25108024] (Functional Assay, ICC, Western Blot, Human)	Functional Assay, ICC, Western Blot	Human
Porichis F, Kwon DS, Zupkosky J, Tighe DP, McMullen A, Brockman MA, Pavlik DF, Rodriguez-Garcia M, Pereyra F, Freeman GJ, Kavanagh DG, Kaufmann DE Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood, 2011-06-07;118(4):965-74. 2011-06-07 [PMID: 21652684] (Flow Cytometry, Human)	Flow Cytometry	Human

Array AF2319

• LAG-3 Antibodies
• LAG-3 Antibody Pack
• LAG-3 ELISA Kit
• LAG-3 Lysate
• LAG-3 Protein
• LAG-3 ELISA
• LAG-3 Proteins and Enzymes